Adoptive T-cell therapy for cancer: the era of engineered T cells
Open accessThe DOI matches its Crossref record; 133 of the 134 references it cites were found in a registry or an index.
Abstract
Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination. It is however clear that several mechanisms encompassing both central and peripheral tolerance limit antitumor immunity, often resulting into progressive diseases. Adoptive T-cell therapy with either allogeneic or autologous T cells can transfer therapeutic immunity. To date, genetic engineering of T cells appears to be a powerful tool for shaping tumor immunity. In this review, we discuss the most recent achievements in the areas of suicide gene therapy, and TCR-modified T cells and chimeric antigen receptor gene-modified T cells. We provide an overview of current strategies aimed at improving the safety and efficacy of these approaches, with an outlook on prospective developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TCR-engineered T cells or CAR-engineered T cells increase the efficacy of the antitumor immune response (79).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Research works printed but not linked: 3
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Eur. J. Immunol. 2015. 45: 2457-2469 REVIEWS 2469 119
- Milan, Italy e-mail: chiara.bonini@hsr.it See all the ECI 2015 Reviews at http://onlinelibrary.wiley.com/journal/ 10.1002/(ISSN)1521-4141/homepage/eci2015.htm · doi:10.1002/(issn)1521-4141/homepage/eci2015.htm
Cited by
Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., de la Cámara, R., Corbacioglu, S., Dolstra, H., Duarte, R., Glass, B., Greco, R., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01227-8 · Cited by 429
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Duarte, R. F., Dufour, C., Gennery, A., Kröger, N., Kuball, J., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.34 · Cited by 395
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.03.001 · Cited by 246
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., Corbacioglu, S., Duarte, R., Dolstra, H., Lankester, A. C., Mohty, M., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0826-4 · Cited by 187
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0465-9 · Cited by 173
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 183
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Basak, G. W., Bonini, C., Duarte, R. F., Dufour, C., Kröger, N. M., Kuball, J. H. E., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0153-1 · Cited by 159
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Zhao, Q., Jiang, Y., Xiang, S., Kaboli, P. J., Shen, J., Zhao, Y., Wu, X., Du, F., Li, M., Cho, C. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658753 · Cited by 165
“Autologous immune response to activate the suicide gene may result in transduced T-cell elimination, and therefore, reduces their therapeutic efficiency (76).”
BackgroundGut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
“TCR-engineered T cells or CAR-engineered T cells increase the efficacy of the antitumor immune response (79).”
BackgroundBaboo, J., Kilbride, P., Delahaye, M., Milne, S., Fonseca, F., Blanco, M., Meneghel, J., Nancekievill, A., Gaddum, N., & Morris, G. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-39957-x · Cited by 130
Passweg, J. R., Baldomero, H., Atlija, M., Kleovoulou, I., Witaszek, A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Ciceri, F., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02524-2 · Cited by 100
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Rath, J. A., & Arber, C. (2020) · Cells · doi:10.3390/cells9061485 · Cited by 115
Passweg, J. R., Baldomero, H., Ciceri, F., Corbacioglu, S., de la Cámara, R., Dolstra, H., Glaß, B., Greco, R., McLornan, D. P., Neven, B., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-01943-3 · Cited by 89
Passweg, J. R., Baldomero, H., Ciceri, F., de la Cámara, R., Glaß, B., Greco, R., Hazenberg, M. D., Kałwak, K., McLornan, D. P., Neven, B., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02248-9 · Cited by 88
Macrophages as a “weapon” in anticancer cellular immunotherapy
Aminin, D. L., & Wang, Y. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12405 · Cited by 85
Passweg, J. R., Baldomero, H., Chabannon, C., Corbacioglu, S., de la Cámara, R., Dolstra, H., Glaß, B., Greco, R., Mohty, M., Neven, B., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01604-x · Cited by 71
Prodrugs and prodrug-activated systems in gene therapy
Sheikh, S., Ernst, D. M., & Keating, A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.006 · Cited by 74
Pearson, A. D. J., Rössig, C., Lesa, G. M., Diede, S. J., Weiner, S. L., Anderson, J., Gray, J. C., Geoerger, B., Minard‐Colin, V., Marshall, L. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.029 · Cited by 73
“In principle, antigenspecific T cells can be activated in vivo by bispecific T cell engagers [79] or generated by CAR T cells [80e83] and TCR gene-modified T cells [84].”
BackgroundRoth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 70
“The use of CAR-modified Tcells avoids this limit [79] but needs to be improved as their half-life is very limited.”
BackgroundFuture of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S., Pelt, S. N. V., Hanley, P. J., & Cruz, C. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00196 · Cited by 62
“A similar technology involves using high affinity T cell receptors (TCRs) and introducing these into cells (19).”
MethodRegulatory T cell therapy: Current and future design perspectives
Rana, J., & Biswas, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104193 · Cited by 62
Pushing the Limits of Cancer Therapy: The Nutrient Game
Lettieri‐Barbato, D., & Aquilano, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00148 · Cited by 60
Development of adaptive immune effector therapies in solid tumors
Comoli, P., Chabannon, C., Koehl, U., Lanza, F., Urbano-Ispizúa, Á., Hudecek, M., Ruggeri, A., Secondino, S., Bonini, C., & Pedrazzoli, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz285 · Cited by 65
Jiang, Q., Zhang, C., Wang, H., Peng, T., Li, Z., Wang, Y., Han, W., & Shi, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01196 · Cited by 57
“ACT has recently been adapted to use gene-modified T cells, with both TCR- and CAR-based therapy achieving tremendous success against B cell malignancies (32); however, this approach has been less successful against solid cancer, partly due to the immunosuppressive TME (4, 33).”
BackgroundEvolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
Sun, Y., Li, F., Sonnemann, H. M., Jackson, K. R., Talukder, A. H., Katailiha, A. S., & Lizee, G. A. (2021) · Cells · doi:10.3390/cells10092379 · Cited by 65
“If tumor-specific TCRs can be rapidly re-introduced into autologous T cells, this would allow for ‘transplantation’ of the tumor-reactive TCR repertoire from exhausted T cells into a fitter T cell population [46].”
BackgroundOlivera, I., Bolaños, E., González-Gomariz, J., Hervás‐Stubbs, S., Mariño, K. V., Luri‐Rey, C., Etxeberría, I., Cirella, A., Egea, J., Glez‐Vaz, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100978 · Cited by 54
A homing system targets therapeutic T cells to brain cancer
Samaha, H., Pignata, A., Fousek, K., Ren, J. P., Lam, F. W., Stossi, F., Dubrulle, J., Salsman, V. S., Krishnan, S., Hong, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0499-y · Cited by 43
RetractedA Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics
Ramesh, P., Shivde, R. S., Jaishankar, D., Saleiro, D., & Poole, I. C. L. (2021) · Cancers · doi:10.3390/cancers13040821 · Cited by 45
“Based on their function, cytokines can be divided into subgroups: lymphokines, monokines, chemokines, interleukins (IL), and interferons (IFNs) [2].”
BackgroundNajafi, S., & Mortezaee, K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122387 · Cited by 43
DNA methylation signatures of Prostate Cancer in peripheral T-cells
Mehdi, A., Cheishvili, D., Arakelian, A., Bismar, T. A., Szyf, M., & Rabbani, S. A. (2020) · BMC Cancer · doi:10.1186/s12885-020-07078-8 · Cited by 39
DNA methylation signatures of breast cancer in peripheral T-cells
Parashar, S., Cheishvili, D., Mahmood, N., Arakelian, A., Tanvir, I., Khan, H. A., Kremer, R. B., Mihalcioiu, C. L. D., Szyf, M., & Rabbani, S. A. (2018) · BMC Cancer · doi:10.1186/s12885-018-4482-7 · Cited by 42
“The peripheral cells of the immune system constantly patrol the body to protect it from pathogens, exogenous antigens and are able to identify the transformed cells [27].”
BackgroundMethodCancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials
Yang, M., Zhang, C., Wang, R., Wu, X., Li, H., & Yoon, J. (2023) · Small Methods · doi:10.1002/smtd.202201381 · Cited by 41
How antigen specificity directs regulatory T‐cell function: self, foreign and engineered specificity
Hoeppli, R. E., MacDonald, K. G., Levings, M. K., & Cook, L. E. (2016) · HLA · doi:10.1111/tan.12822 · Cited by 35
“If the T-cell receptor (TCR) is non-functional and/or unable to recognize self-MHC, then the absence of TCR signal results in cells ‘dying by neglect’ (reviewed in Ref (5)).”
MethodInfluentialA Perspective of Immunotherapy for Prostate Cancer
Silvestri, I., Cattarino, S., Giantulli, S., Nazzari, C., Collalti, G., & Sciarra, A. (2016) · Cancers · doi:10.3390/cancers8070064 · Cited by 34
“Studies are also aimed to ameliorate CAR using humanized antibodies binding multiple antigens [142,143].”
BackgroundUnleash the power of the mighty T cells-basis of adoptive cellular therapy
Sukari, A. W., Abdallah, N. H., & Nagasaka, M. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.015 · Cited by 35
Shen, Y., Wang, H., Chen, X., Li, W., & Chen, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217935 · Cited by 33
“related to the improved prognosis of cancer patients and has been used for targeted cancer therapy.(37,38) However, SIR from cancer cells is a significant cause of immuno-”
MethodChimeric antigen receptor T-cell therapy for T-ALL and AML
Wei, W., Yang, D. F., Chen, X., Liang, D., Zou, L., & Zhao, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.967754 · Cited by 32
“When compared wi th TCRs , CARs are major histocompatibility complex (MHC) independent and can recognize targeted antigens expressed on the cell surface (48, 49), which is in contrast to TCRs that only recognize natural”
BackgroundThe Safety of available immunotherapy for the treatment of glioblastoma
Farber, S. H., Elsamadicy, A. A., Atik, A. F., Suryadevara, C. M., Chongsathidkiet, P., Fecci, P. E., & Sampson, J. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1273898 · Cited by 30
“ism of tumor immune escape – MHC downregulation [52].”
BackgroundManzo, T., Sturmheit, T., Basso, V., Petrozziello, E., Michelini, R. H., Riba, M., Freschi, M., Elia, A. R., Grioni, M., Curnis, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0725 · Cited by 25
“5 against B-cell malignancies, lymphomas, metastatic melanoma, sarcomas, and neuroblastoma (7-9).”
BackgroundCombination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 29
Chimeric antigen receptor T cell: A cancer immunotherapy
Singh, S., Khasbage, S. U., Kaur, R. J., Sidhu, J. K., & Bhandari, B. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_531_20 · Cited by 22
“[6] CAR‑”
Baudequin, T., Nyland, R., & Ye, H. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107735 · Cited by 22
Belgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 25
“…exploited in recent times through the therapeutic use of tumor-targeted advanced-therapy medicinal products (ATMPs), such as T cells that have been genetically modified to express chimeric antigen receptors (CARs) or natural T cell receptors (TCRs) bearing tumor-associated antigens [1].”
BackgroundMarrow-Infiltrating Lymphocytes – Role in Biology and Cancer Therapy
Borrello, I., & Noonan, K. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00112 · Cited by 21
Meng, X., Lei, Y., Zhang, X., Sun, K., Zhang, L., & Wang, Z. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101149 · Cited by 24
Immune modulation by dendritic-cell-based cancer vaccines
Kumar, C., Kohli, S., Bapsy, P. P., Vaid, A. K., Jain, M. M., Attili, V. S. S., & Sharan, B. (2017) · Journal of Biosciences · doi:10.1007/s12038-017-9665-x · Cited by 20
“Hence, autologous T-cells expressing TCR or chimeric antigen receptor (CAR) are being exploited to improved efficacy of T-cell-based vaccines in clinical settings (Bonini and Mondino 2015).”
BackgroundCellular immunotherapies for cancer
Berraondo, P., Labiano, S., Minute, L., Etxeberría, I., Vásquez, M., Sánchez-Arráez, Á., Teijeira, Á., & Melero, I. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1306619 · Cited by 20
“Alloreactivity of T cells from donors has been the cause of the toxicity and graft versus host disease (GVHD) effects found upon treatment with such therapy.(22)”
BackgroundMethodBolm, L., Käsmann, L., PAYSEN, A., Karapetis, C. S., Rades, D., Wellner, U. F., Keck, T., Watson, D. I., Hummel, R., & Hussey, D. J. (2018) · Anticancer Research · doi:10.21873/anticanres.12588 · Cited by 18
Schmetterer, K. G., Goldhahn, K., Ziegler, L. S., Gerner, M. C., Schmidt, R. L. J., Themanns, M., Zebedin-Brandl, E. M., Trapin, D., Leitner, J. M., Pickl, W. F., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01790 · Cited by 19
“Tumor-mediated immunosuppression also poses a major impediment in the development of adaptive immunotherapy protocols (5, 6).”
BackgroundChimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview
Cortés-Hernández, A., Alvarez-Salazar, E. K., & Soldevila, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0759-6_14 · Cited by 18
Das, C. R., Tiwari, D., Dongre, A., Khan, M. A., Husain, S. A., Sarma, A., Bose, S., & Bose, P. D. (2018) · Viral Immunology · doi:10.1089/vim.2017.0151 · Cited by 21
“There are studies that have demonstrated that the immune system can recognize and eliminate aberrant cancer cells arising within the human body (7).”
Reddy, S. R., Llukmani, A., Hashim, A., Haddad, D. R., Patel, D. S., Ahmad, F., Sneineh, M. A., & Gordon, D. K. (2021) · Cureus · doi:10.7759/cureus.13552 · Cited by 25
“Others include CAR-T cell-related encephalopathy syndrome, macrophage activation syndrome, hemophagocytic lymphohistiocytosis, graft-versus-host disease, on-target/off-tumor toxicity, anaphylaxis, and infections [3,8,23,24].”
BackgroundLiberio, N., Robinson, H., Nugent, M., Simpson, P. M., Margolis, D. A., Malarkannan, S., Keever-Taylor, C. A., & Thakar, M. S. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27950 · Cited by 16
Regulatory Cell Therapy in Organ Transplantation: Achievements and Open Questions
Fortunato, M., Morali, K., Passeri, L., & Gregori, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641596 · Cited by 18
“Ectopic expression of a TCR, used to engineer T cell specificity in the field of cancer immunotherapy (47), has been applied also to Tregs.”
MethodThe promises of immunotherapy in gliomas
Mildenberger, I. C., Bunse, L., Ochs, K., & Platten, M. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000491 · Cited by 16
Interleukin-7 Unveils Pathogen-Specific T Cells by Enhancing Antigen-Recall Responses
Terrazzini, N., Mantegani, P., Kern, F., Fortis, C., Mondino, A., & Caserta, S. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy096 · Cited by 18
“We previously suggested that among other CD132-cytokines, IL-7 played nonredundant roles and outperformed IL-2 in driving Ag-experienced T-cell accumulation and mediating the expansion of less differentiated cells useful for gene therapy [26, 30].”
BackgroundChimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review
Sharma, R., Suravarjhula, L., Banerjee, M., Kumar, G., & Kumar, N. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230220092125 · Cited by 14
Alberti, C. (2016) · Il Giornale di Chirurgia - Journal of the Italian Association of Hospital Surgeons · doi:10.11138/gchir/2016.37.5.225 · Cited by 13
Kowalski, J. P., McDonald, M. G., Whittington, D., Guttman, M., Scian, M., Girhard, M., Hanenberg, H., Wiek, C., & Rettie, A. E. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00330 · Cited by 13
Kaeuferle, T., Stief, T. A., Canzar, S., Kutlu, N. N., Willier, S. M., Stenger, D., Ferrada‐Ernst, P., Habjan, N., Peters, A. E., Busch, D. H., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1372 · Cited by 17
TIME Is Ticking for Cervical Cancer
Kumar, V., Bauer, C., & Stewart, J. H. (2023) · Biology · doi:10.3390/biology12070941 · Cited by 13
Development of Cancer Immunotherapies
DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 16
Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system
Han, W., Li, W., Zhang, X., Du, Z., Liu, X., Zhao, X., Wen, X., Wang, G., Hu, J., & Cui, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14746 · Cited by 10
“As demonstrated recently, success in tumor gene therapy has been achieved by harnessing endogenous immune mechanisms [13, 14].”
BackgroundAdvances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
Liu, F., Miao, X., Han, L., & Song, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390006 · Cited by 9
Cancer Immunotherapy using Tumor Antigen-Reactive T Cells
Choi, B. K., Kim, S.-H., Kim, Y. H., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0130 · Cited by 8
de Montes, A. L. R. G., & Spencer, L. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0043 · Cited by 10
Gene-modified, cell-based therapies—an overview
Powell, A. B., Williams, K., & Cruz, C. C. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.001 · Cited by 7
Features and therapeutic potential of T-cell receptors in high-grade glioma
Zhang, J., Zhong, X., Yang, S., Kang, X., Li, Y., Chen, J., & Li, W. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000282 · Cited by 6
“In fact, TCR-engineered T-cell (TCR-T) immunotherapy is based on the application of artificially modified TCRs and is especially suitable for solid tumors.([16-20]) Therefore, the study on TCRs is an important way to find potential therapeutic targets for various tumors.”
BackgroundApplication of Biomimetic Nanoparticles based on the Cell Membrane in Tumor Therapy
Gong, Y., & Huang, J. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230427114622 · Cited by 6
Schossig, P., Coskun, E., Arsenić, R., Horst, D. A., Sehouli, J., Bergmann, E. C., Andresen, N., Sigler, C., Busse, A., Keller, U. B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032292 · Cited by 7
“The majority of ACT approaches are conducted as adoptive transfer of autologous T cells with a transgenic, tumor associated antigen (TAA)-specific T cell receptor (TCR), a strategy, which is considered the most effective option to apply a targeted T cell therapy in cancer [8,9].”
BackgroundFlow cytometry detection and quantification of CAR T cells into solid tumors
Tokarew, N. J. A., Gosálvez, J. S., Nottebrock, A., Briukhovestka, D., Endres, S., Cadilha, B. L., & Kobold, S. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.06.015 · Cited by 4
Ahn, S., Vo, M.-C., Nguyen, V., Tran, V.-D.-H., Duc, T. N., Kim, M., Song, G., Ahn, J., Yang, D., Kim, H., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102475 · Cited by 3
“This natural enrichment provides a key advantage over PBLs, as supported by studies showing higher tumor reactivity of BM-derived T cells compared to PBLs [8,9].”
Wang, W., Deng, Z., Wang, J., Zhang, L., Bao, L., Xu, B., Zhu, H. H., Guo, Y., & Zhang, W. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i9.1008 · Cited by 3
Introductory Chapter: Advances in Hematologic Malignancies
Hamid, G. A., & Hariri, F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88777 · Cited by 5
“Whenever effective, this procedure prompts long-term remission [38, 39].”
Smart Biomaterials as Immunomodulators in Cancer Therapy
Sharma, A., Parekh, B. K., Patil, V., Renuka Jyothi, S., Nayak, P. P., Janney, J. B., Singh, G., & Al‐Shaker, H. (2025) · Immunology · doi:10.1111/imm.70068 · Cited by 3
“CAR T cells also demonstrate long-term persistence in vivo, enhancing their durability and efficacy [39, 40].”
Tumor-induced immune escape mechanisms and translational immunotherapeutic strategies
Yousefi, M., Farahpour, M. R., Alizadeh, N., Abedian, A., & Baradaran, B. (2026) · Discover Oncology · doi:10.1007/s12672-026-05518-8 · Cited by 2
“Concurrently, adoptive cell transfer (ACT) treatments like chimeric antigen receptor T cells (CAR-T) and T-cell receptor (TCR)-engineered cells have shown a lot of promise, especially in blood cancers [22, 23].”
EVOLVING ROLE OF CAR T-CELL IN CANCER IMMUNOTHERAPY
Sulaiman, A. A., Al-SHAMAA, Z. A., & Al-ASSADI, M. E. (2019) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2019v11i6.36351 · Cited by 2
“Besides that, CAR-T cells not require the aid of HLA expression for recognition of cell surface molecules, so they can avoid T cell immune surveillance mediated by hiding HLA or other molecules involved in antigen processing and presentation [92].”
BackgroundArmored CAR-T Cells: Fortifying the Future of Cancer Therapy
Kumar, D., Gupta, V., Tanwar, R., Jaiswal, N. K., & Gupta, S. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624404279251016163549 · Cited by 1
Shariati, A., Homaei, A., Khezrpour, A., Azizi, N., Khani, P., Shariati, F. S., Rafiee, M., Afkhami, H., Yousefi, M. H., Saeidi, F., et al. (2026) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2026.100382 · Cited by 1
Murias, C., Arkenau, H., Dutoit, V., & Patrikidou, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89074 · Cited by 1
“TIL therapy has shown some clinical evidence of efficacy in the treatment of melanoma [43] and cervical cancer [44], with the LN-145 TIL therapy recently obtaining breakthrough therapy designation by FDA, while its potential is being further investigated.”
BackgroundMethodImproving adenovirus-based immunotherapies for treatment of solid tumors
Siurala, M. (2017) · Helda - University of Helsinki Institutional Repository
Engineering Macrophages for Cell-Based Therapies
Lee, S. (2017) · eScholarship (California Digital Library)
T regulatory cell therapy in preclinical and clinical pancreatic islet transplantation
Fousteri, G., & Cicalese, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00063-0
Cancer Immunotherapy and Biological Cancer Treatments
Arnouk, H. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77856 · Cited by 1
From mouse to human: Metabolic targeting of cancer with TEG-based immunotherapy
Johanna, I. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/948
Haemopoietic stem cell transplantation
Gordon‐Smith, E. C., & Morris, E. C. (2020) · doi:10.1093/med/9780198746690.003.0549
Clinical application of cell‐based therapies opportunities and challenges
Gao, J., & Wu, D. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.110
Towards inmunotherapeutic exploitation strategies of rotumor and antitumor cytokines
Olivera, I. (2023) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/69099 · Cited by 3
CAR T cells and metabolic programming: A review
Hatami, S., Kazemi, F., Doroudgar, P., Shushtari, S. S., & Atashzar, M. R. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-ctc-3155
Memmos, N., Kaveh, K., Webber, B. R., Moriarity, B. S., & Odde, D. J. (2026) · Physical Biology · doi:10.1088/1478-3975/ae4705
“There are two main approaches: one where immune cells are harvested directly from cancer patients to treat their own disease, i.e. autologous cell therapy, or another where immune cells are obtained from healthy donors, i.e. allogeneic cell therapy [2].”
New trends in melanoma immunotherapy
Řandová, L., & Kodet, O. (2026) · Onkologie · doi:10.36290/xon.2026.001
Jacoberger-Foissac, C. (2018) · theses.fr (ABES) · doi:10.70675/6f6b5670zeecbz4ac9z8760z516f6d526862 · Cited by 1
Metadata
- Authors
- Bonini, C., & Mondino, A.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Corresponding author
- Bonini, Chiara
- Mondino, Anna
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2015-08-21
- Volume
- 45
- Issue
- 9
- Pages
- 2457-2469
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1957268835
- Cited by
- 93
- References
- 134
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 10 · 2022: 10 · 2021: 10 · 2020: 8 · 2019: 16 · 2018: 12 · 2017: 8 · 2016: 7
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG 11970 and IG 15883)
- Fifth Framework Programme (LSHC-CT-2005-018914 ATTACK)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- adoptive T cell therapy, engineered T cells, suicide gene therapy, chimeric antigen receptor T cells, antitumor immunity, tumor immune evasion, allogeneic T cells, autologous T cells
- MeSH terms
- Antigens, Neoplasm, Forecasting, Humans, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Gene Expression, Immunotherapy, Adoptive, Genes, Transgenic, Suicide, Mutant Chimeric Proteins, Cell Engineering, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.